Plasmapheresis
CRRT
LCAP
- Features
- Performances
- Specifications
- References
- Shibata et al.
- Cellsorba.
- Therap Apher Dial. 7:44-7, 2003.
- Matsumoto et al.
- Multivariate analysis for factors predicting rapid response of leukocytapheresis in patients with steroid-resistant ulcerative colitis: a multicenter prospective open-label study.
- Ther Apher Dial. 12:484-90, 2008.
- Kosaka et al.
- Effect of leukocytapheresis therapy using a leukocyte removal filter in Crohn's disease.
- Intern Med. 38:102-11, 1999.
- Hidaka et al.
- Dynamic changes in cytokine levels in serum and synovial fluid following filtration leukocytapheresis therapy in patients with rheumatoid arthritis.
- J Clin Apheresis. 16:74-81, 2001.
- Yamaji et al.
- Fluctuations in the peripheral blood leukocyte and platelet counts in leukocytapheresis in healthy volunteers.
- Ther Apher. 6:402-12, 2002.
- Shibata et al.
- Cellsorba.
- Therap Apher Dial. 7:44-7, 2003.
- Sawada et al.
- Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column.
- Current Pharmaceutical Design 9:307-21, 2003.
- Fukunaga et al.
- Poorly controlled ulcerative colitis treated by colectomy during remission induced by extracorporeal leukocyte removal therapy.
- J Gastroenterol. 38:684-9, 2003.
- Kohgo et al.
- Leukocytapheresis for treatment of IBD. J Gastroenterol.
- 38 Suppl 15:51-4, 2003.
- Sawada K.
- Leukocytapheresis as an adjunct to conventional medication for inflammatory bowel disease. Dis Colon Rectum.
- 46 Suppl: S66-77, 2003.
- Andoh et al.
- Suppression of interleukin-1beta- and tumor necrosis factor-alpha-induced inflammatory responses by leukocytapheresis therapy in patients with ulcerative colitis.
- J Gastroenterol. 39:1150-7, 2004.
- Sawada et al.
- Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment.
- Am J Gastroenterol. 100:1362-9, 2005.
- Sawada et al.
- Leukocytapheresis (LCAP) for management of fulminant ulcerative colitis with toxic megacolon.
- Dig Dis Sci. 50:767-73, 2005.
- Ashizuka et al.
- Leukocytapheresis for ulcerative colitis: a comparative study of anticoagulant (nafamostat mesilate vs. dalteparin sodium) for reducing clinical complications.
- Ther Apher Dial. 10:54-8, 2006.
- Sandborn WJ.
- Preliminary data on the use of apheresis in inflammatory bowel disease.
- Inflamm Bowel Dis.12 Suppl 1:S15-21, 2006.
- Matsumoto et al.
- Multivariate analysis for factors predicting rapid response of leukocytapheresis in patients with steroid-resistant ulcerative colitis: a multicenter prospective open-label study.
- Ther Apher Dial. 12:484-90, 2008.
- Mitsuyama et al.
- Mobilization of bone marrow cells by leukocytapheresis in patients with ulcerative colitis.
- Ther Apher Dial. 12:271-7, 2008.
- Mitsuyama et al.
- Therapeutic leukocytapheresis in inflammatory bowel disease: clinical efficacy and mechanisms of action.
- Cytotherapy. 11:229-37, 2009.
- Muratov et al.
- Safety and tolerability of a modified filter-type device for leukocytapheresis using ACD-A as anticoagulant in patients with mild to moderately active ulcerative colitis. Results of a pilot study.
- J Clin Apher. 25:287-93, 2010.
Trademark
Cellsorba is a trademark of Asahi Kasei Medical Co., Ltd.
Cellsorba EX
Please feel free to send us any questions you may have about our products and support.
